Global COPD treatment market to hit $11.2 billion by 2021, says GBI Research
3 December 2015 | By Victoria White
GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021...
List view / Grid view
News
TxCell reacquires full rights to Ovasave from Trizell
3 December 2015 | By Victoria White
TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave...
Cytos Biotechnology and Kuros Biosurgey to combine
3 December 2015 | By Victoria White
The combined company has an attractive late stage pipeline and several products at preclinical stage...
NICE says ‘no’ to asfotase alfa in draft guidance
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
J&J announces new global commitments to end HIV infection in girls and women
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
Second cohort of NKG2D CAR T-Cell Phase I Trial commences
2 December 2015 | By Victoria White
Celyad has announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating it's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma...
Trulicity effective as add-on treatment to sulfonylurea in study
New data from a completed Phase 3 trial show Lilly’s Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering haemoglobin A1c (A1C) from baseline after 24 weeks of treatment.
Victoza provides greater glycaemic control than SGLT-2 inhibitors
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...
Join CI Precision and PT Electronics PVT Ltd at P-MEC India in Mumbai, 1 – 3 Dec 2015
1 December 2015 | By CI Precision
CI Precision and our channel partner PT Electronics are exhibiting at CPhi P-MEC India 2015 in Mumbai on 1-3 December...
Tecan helps Repsol to drive the fuels of the future
1 December 2015 | By Tecan
The Madrid Technology Center of global energy company Repsol relies on two Freedom EVO® platforms for colony picking and enzymatic assays for research into fossil fuel alternatives, using Tecan’s 350 µl nested LiHa disposable tips to achieve extended walkaway times...
Dolomite celebrates 10 years of microfluidic innovation
1 December 2015 | By Dolomite
Dolomite, part of the Blacktrace group of companies, is celebrating a decade of excellence in the design and manufacture of novel, high quality microfluidic products, including individual components such as pumps, chips, connectors, temperature controllers and sensors, software solutions and complete microfluidic systems...
Black Swan Analysis has added to its Epiomic Epidemiology series of reports with Atopic Dermatitis forecast in 17 major markets 2015-2025
1 December 2015 | By Black Swan Analysis
Research and Markets has announced the addition of the "Epiomic Epidemiology Series: Atopic Dermatitis Forecast in 17 Major Markets 2015-2025" report to their offering...
Opioid-induced constipation treatment market to rise to $652.4 million by 2019
1 December 2015 | By Victoria White
GlobalData says the rising number of opioid-induced constipation sufferers is largely down to overall population increase...
Roche and Upsher-Smith to develop VAP-1 inhibitor
1 December 2015 | By Victoria White
The novel, oral small molecule inhibitor of VAP-1 is a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases...
Biovica’s DiviTum selected for palbociclib breast cancer trial
1 December 2015 | By Victoria White
The assay has been selected by the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG) to be part of a trial studying the effects of palbociclib in breast cancer...
